Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa) are widely-prescribed for the treatment of in cancer patients, chronic kidney failure patients and HIV patients. These drugs are called ESAs, and are manufactured by Amgen, based in Thousand Oaks, California. ESAs first hit the market over fifteen years ago, and they recently accounted for more than $10 billion in sales in a single year. Serious safety concerns about ESAs started surfacing in 2004. Then, in November of 2006, the FDA issued an official Alert regarding the three drugs. Studies had indicated an increased risk of death, stroke, heart attack and blood clots in patients with chronic kidney failure, when higher-than-recommended doses of ESAs had been taken. Other studies showed accelerated tumor growth in head and neck cancer patients when higher than recommended doses were taken. But even when taking ESAs at the recommended doses, cancer patients who weren’t receiving chemotherapy faced an increased risk of death. In addition, patients who underwent orthopedic surgery were at a higher risk for blood clots.

These drugs have been prescribed to thousands and thousands of people over the years. That means that housands of patients are at risk of the devastating and potentially-fatal side effects of ESAs. If you believe ESA use has put you or someone you care about in danger, please contact us through this website to obtain a free consultation and learn more.

"YOUR FUTURE DEPENDS ON WHAT YOU DO TODAY"
Don't let them mistreat you or your loved ones.
Just call 1-(800)-827-7898.
We are here to help you and answer your questions.